U.S. Circulating Tumor Cells Market Size, Share & Trends Analysis Report By Application (Clinical/Liquid Biopsy, Research), By Specimen (Bone Marrow, Blood), By Product, By Technology, And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. U.S. Circulating Tumor Cells Market: Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Technology
                        1.2.2. Application
                        1.2.3. Product
                        1.2.4. Specimen
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                        1.4.5. Details of primary research
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity flow analysis (Model 1)
                        1.7.2. Approach 1: Commodity flow approach
                        1.7.3. Volume price analysis (Model 2)
                        1.7.4. Approach 2: Volume price analysis
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. U.S. Circulating Tumor Cells Market: Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Snapshot
                    2.3. Competitive Insights
Chapter 3. U.S. Circulating Tumor Cells Market: Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                        3.2.1. Market Driver Analysis
                            3.2.1.1. Advancements in chip technology
                            3.2.1.2. Expanding applications of CTCs
                            3.2.1.3. Growing demand for early and rapid cancer diagnosis
                            3.2.1.4. Growing incidence of cancer
                        3.2.2. Market Restraint Analysis
                            3.2.2.1. Consistency-related challenges in CTC detection and enrichment
                            3.2.2.2. Higher preference for Point-of-Care (POC) testing and nonavailability of POC adaptable CTC tests
                            3.2.2.3. Lower applicability of CTCs in rare cancers
                    3.3. Circulating Tumor Cells Market Analysis Tools
                        3.3.1. Industry Analysis - Porter’s
                        3.3.2. PESTEL Analysis
                        3.3.3. COVID-19 Impact Analysis
Chapter 4. U.S. Circulating Tumor Cells Market: Technology Estimates & Trend Analysis
                    4.1. Technology Market Share, 2023 & 2030
                    4.2. U.S. Circulating Tumor Cells Market by Technology Outlook
                    4.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                        4.3.1. CTC Detection & Enrichment Methods
                            4.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.3.1.2. Immunocapture (Label-based)
                                4.3.1.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                                4.3.1.2.2. Positive Selection
                                    4.3.1.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                                4.3.1.2.3. Negative Selection
                                    4.3.1.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.3.1.3. Size-based Separation (Label-free)
                                4.3.1.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                                4.3.1.3.2. Membrane-based
                                    4.3.1.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                                4.3.1.3.3. Microfluidic-based
                                    4.3.1.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.3.1.4. Density-based Separation (Label-free)
                                4.3.1.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.3.1.5. Combined Methods
                                4.3.1.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                        4.3.2. CTC Direct Detection Methods
                            4.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.3.2.2. SERS
                                4.3.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.3.2.3. Microscopy
                                4.3.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.3.2.4. Others
                                4.3.2.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                        4.3.3. CTC Analysis
                            4.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. U.S. Circulating Tumor Cells Market: Application Estimates & Trend Analysis
                    5.1. Application Market Share, 2023 & 2030
                    5.2. U.S. Circulating Tumor Cells Market by Application Outlook
                    5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                        5.3.1. Clinical/ Liquid Biopsy
                            5.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                            5.3.1.2. Risk Assessment
                                5.3.1.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                            5.3.1.3. Screening and Monitoring
                                5.3.1.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                        5.3.2. Research
                            5.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                            5.3.2.2. Cancer Stem Cell & Tumorogenesis Research
                                5.3.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                            5.3.2.3. Drug/Therapy Development
                                5.3.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. U.S. Circulating Tumor Cells Market: Product Estimates & Trend Analysis
                    6.1. Product Market Share, 2023 & 2030
                    6.2. U.S. Circulating Tumor Cells Market by Product Outlook
                    6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                        6.3.1. Kits & reagents
                            6.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                        6.3.2. Blood collection tubes
                            6.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                        6.3.3. Devices or systems
                            6.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. U.S. Circulating Tumor Cells Market: Specimen Estimates & Trend Analysis
                    7.1. Specimen Market Share, 2023 & 2030
                    7.2. U.S. Circulating Tumor Cells Market by Specimen Outlook
                    7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                        7.3.1. Blood
                            7.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                        7.3.2. Bone marrow
                            7.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                        7.3.3. Other body fluids
                            7.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
                    8.1. Recent Developments & Impact Analysis, By Key Market Participants
                    8.2. Company/Competition Categorization
                    8.3. Vendor Landscape
                        8.3.1. List of key distributors and channel partners
                        8.3.2. Key customers
                        8.3.3. Key company position analysis, 2023
                    8.4. Company Profiles
                        8.4.1. QIAGEN
                            8.4.1.1. Company overview
                            8.4.1.2. Financial performance
                            8.4.1.3. Product benchmarking
                            8.4.1.4. Strategic initiatives
                        8.4.2. Bio-Techne Corp.
                            8.4.2.1. Company overview
                            8.4.2.2. Financial performance
                            8.4.2.3. Product benchmarking
                            8.4.2.4. Strategic initiatives
                        8.4.3. Precision for Medicine
                            8.4.3.1. Company overview
                            8.4.3.2. Financial performance
                            8.4.3.3. Product benchmarking
                            8.4.3.4. Strategic initiatives
                        8.4.4. AVIVA Biosciences
                            8.4.4.1. Company Overview
                            8.4.4.2. Financial performance
                            8.4.4.3. Product benchmarking
                            8.4.4.4. Strategic initiatives
                        8.4.5. BIOCEPT, Inc.
                            8.4.5.1. Company overview
                            8.4.5.2. Financial performance
                            8.4.5.3. Product benchmarking
                            8.4.5.4. Strategic initiatives
                        8.4.6. BioCEP Ltd.
                            8.4.6.1. Company overview
                            8.4.6.2. Financial performance
                            8.4.6.3. Product benchmarking
                            8.4.6.4. Strategic initiatives
                        8.4.7. Fluxion Biosciences, Inc.
                            8.4.7.1. Company overview
                            8.4.7.2. Financial performance
                            8.4.7.3. Product benchmarking
                            8.4.7.4. Strategic initiatives
                        8.4.8. Greiner Bio-One International GmbH
                            8.4.8.1. Company overview
                            8.4.8.2. Financial performance
                            8.4.8.3. Product benchmarking
                            8.4.8.4. Strategic initiatives
                        8.4.9. Ikonisys, Inc.
                            8.4.9.1. Company overview
                            8.4.9.2. Financial performance
                            8.4.9.3. Product benchmarking
                            8.4.9.4. Strategic initiatives
                        8.4.10. Miltenyi Biotec
                            8.4.10.1. Company overview
                            8.4.10.2. Financial performance
                            8.4.10.3. Product benchmarking
                            8.4.10.4. Strategic initiatives
                        8.4.11. IVDiagnostics
                            8.4.11.1. Company overview
                            8.4.11.2. Financial performance
                            8.4.11.3. Product benchmarking
                            8.4.11.4. Strategic initiatives
                        8.4.12. BioFluidica
                            8.4.12.1. Company overview
                            8.4.12.2. Financial performance
                            8.4.12.3. Product benchmarking
                            8.4.12.4. Strategic initiatives
                        8.4.13. Canopus Bioscience Ltd.
                            8.4.13.1. Company overview
                            8.4.13.2. Financial performance
                            8.4.13.3. Product benchmarking
                            8.4.13.4. Strategic initiatives
                        8.4.14. Biolidics Limited
                            8.4.14.1. Company overview
                            8.4.14.2. Financial performance
                            8.4.14.3. Product benchmarking
                            8.4.14.4. Strategic initiatives
                        8.4.15. Creativ MicroTech , Inc.
                            8.4.15.1. Company overview
                            8.4.15.2. Financial performance
                            8.4.15.3. Product benchmarking
                            8.4.15.4. Strategic initiatives
                        8.4.16. LungLife AI
                            8.4.16.1. Company overview
                            8.4.16.2. Financial performance
                            8.4.16.3. Product benchmarking
                            8.4.16.4. Strategic initiatives
                        8.4.17. Epic Sciences
                            8.4.17.1. Company overview
                            8.4.17.2. Financial performance
                            8.4.17.3. Product benchmarking
                            8.4.17.4. Strategic initiatives
                        8.4.18. Rarecells Diagnostics
                            8.4.18.1. Company overview
                            8.4.18.2. Financial performance
                            8.4.18.3. Product benchmarking
                            8.4.18.4. Strategic initiatives
                        8.4.19. ScreenCell
                            8.4.19.1. Company overview
                            8.4.19.2. Financial performance
                            8.4.19.3. Product benchmarking
                            8.4.19.4. Strategic initiatives
                        8.4.20. Menarini Silicon Biosystems
                            8.4.20.1. Company overview
                            8.4.20.2. Financial performance
                            8.4.20.3. Product benchmarking
                            8.4.20.4. Strategic initiatives
                        8.4.21. LineaRx, Inc. (Vitatex, Inc.)
                            8.4.21.1. Company overview
                            8.4.21.2. Financial performance
                            8.4.21.3. Product benchmarking
                            8.4.21.4. Strategic initiatives
                        8.4.22. Sysmex Corporation
                            8.4.22.1. Company overview
                            8.4.22.2. Financial performance
                            8.4.22.3. Product benchmarking
                            8.4.22.4. Strategic initiatives
                        8.4.23. STEMCELL Technologies, Inc.
                            8.4.23.1. Company overview
                            8.4.23.2. Financial performance
                            8.4.23.3. Product benchmarking
                            8.4.23.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 U.S. circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 3 U.S. circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 4 U.S. circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 5 U.S. circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. Circulating tumor cells market: market outlook
Fig. 9 U.S. Circulating Tumor Cells Competitive Insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 U.S. Circulating tumor cells market driver impact
Fig. 15 U.S. Circulating tumor cells market restraint impact
Fig. 16 U.S. Circulating tumor cells market strategic initiatives analysis
Fig. 17 U.S. Circulating tumor cells market: Technology movement analysis
Fig. 18 U.S. Circulating tumor cells market: Technology outlook and key takeaways
Fig. 19 U.S. CTC detection & enrichment methods market estimates and forecast, 2018 - 2030
Fig. 20 Immunocapture (label-based) estimates and forecast, 2018 - 2030
Fig. 21 Positive selection market estimates and forecast, 2018 - 2030
Fig. 22 Negative selection estimates and forecast, 2018 - 2030
Fig. 23 Size-based separation (label-free) market estimates and forecast, 2018 - 2030
Fig. 24 Membrane-based estimates and forecast, 2018 - 2030
Fig. 25 Microfluidic-based estimates and forecast, 2018 - 2030
Fig. 26 Density-based Separation (Label-free) estimates and forecast, 2018 - 2030
Fig. 27 Combined Methods estimates and forecast, 2018 - 2030
Fig. 28 CTC direct detection methods estimates and forecast, 2018 - 2030
Fig. 29 SERS estimates and forecast, 2018 - 2030
Fig. 30 Microscopy estimates and forecast, 2018 - 2030
Fig. 31 Others estimates and forecast, 2018 - 2030
Fig. 32 CTC Analysis estimates and forecast, 2018 - 2030
Fig. 33 U.S. Circulating tumor cells Market: Application movement Analysis
Fig. 34 U.S. Circulating tumor cells market: Application outlook and key takeaways
Fig. 35 Clinical/ Liquid Biopsy market estimates and forecasts, 2018 - 2030
Fig. 36 Risk Assessment market estimates and forecasts, 2018 - 2030
Fig. 37 Screening and Monitoring market estimates and forecasts, 2018 - 2030
Fig. 38 Research market estimates and forecasts, 2018 - 2030
Fig. 39 Cancer Stem Cell & Tumorogenesis Research market estimates and forecasts, 2018 - 2030
Fig. 40 Drug/Therapy Development market estimates and forecasts, 2018 - 2030
Fig. 41 U.S. tumor cells Market: Product movement Analysis
Fig. 42 U.S. Circulating tumor cells market: Product outlook and key takeaways
Fig. 43 Kits & reagents market estimates and forecasts, 2018 - 2030
Fig. 44 Blood collection tubes market estimates and forecasts, 2018 - 2030
Fig. 45 Devices or Systems market estimates and forecasts, 2018 - 2030
Fig. 46 U.S. Circulating tumor cells Market: Specimen movement Analysis
Fig. 47 U.S. Circulating tumor cells market: Specimen outlook and key takeaways
Fig. 48 Blood market estimates and forecasts, 2018 - 2030
Fig. 49 Bone marrow market estimates and forecasts, 2018 - 2030
Fig. 50 Other body fluids market estimates and forecasts, 2018 - 2030
Fig. 53 Research and academic institutes market estimates and forecasts, 2018 - 2030
Fig. 54 Hospital and clinics market estimates and forecasts, 2018 - 2030
Fig. 55 Diagnostic centers market estimates and forecasts, 2018 - 2030
Fig. 56 U.S. market estimates and forecasts, 2018 - 2030
Fig. 57 Market position of key market players - Circulating tumor cells market